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The options for investigating solubilised G protein-coupled receptors (GPCRs) by biophysical
techniques have long been hampered by their instability. A thermostabilised adenosine A2A receptor
expressed in insect cells, puriﬁed in detergent and reconstituted into high-density lipoprotein (HDL)
particles was immobilised onto a Surface Plasmon Resonance sensor chip. This allowed measure-
ment of afﬁnities and kinetics for A2A antagonists with afﬁnities ranging from 50 pM to almost
2 lM. Compared with other formats, reproduction of afﬁnities, and dissociation and association rate
constants are good, reasonable and poor respectively, indicating stabilised receptors in HDL
particles are useful for investigating speciﬁc aspects of GPCR-ligand interactions.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
G protein-coupled receptors (GPCRs) are the targets of around
30–40% of all marketed drugs [1]. However, many approaches suc-
cessfully applied to drug discovery for soluble proteins [2] have
had limited impact on GPCR targets, primarily due to the difﬁculty
in obtaining pure, active, membrane-free receptors for structural
and biophysical investigations. Recent developments in protein
engineering and handling have led to crystallisation and structure
determination for more than 20 GPCRs [3–5], with one technique,
conformational thermostabilisation [6], also allowing the genera-
tion of solubilised GPCRs for investigation by multiple biophysical
techniques. One of these, Surface Plasmon Resonance (SPR), islabel-free and requires only a few micrograms of protein to gener-
ate binding afﬁnity and kinetics data in real time. SPR has been
used with detergent solubilised GPCRs for Biophysical Mapping
of ligand binding sites [7], screening of fragment libraries [8] and
kinetic proﬁling of compounds [9].
While detergent solubilised GPCRs have been extremely useful
for studying ligand binding, it is now possible to produce mem-
brane proteins in reconstituted high-density lipoprotein (rHDL)
particles. rHDLs are self-assembled discoidal fragments of nano-
lipid bilayers that are stabilised in solution by amphipathic helical
scaffold proteins. They are stable and highly soluble membrane
mimetics with controlled lipid composition. A broad range of
membrane proteins have already proven to remain monodisperse
and active after reconstitution into such native-like bilayer parti-
cles [10,11]. However, only four have been so far self-assembled
into rHDLs for the purpose of SPR studies: the tissue factor (TF)
[12], the glycolipid receptor GM1 [13], the CD4 receptor [14] and
the neurotensin receptor type 1 [15]. All of these investigations
were limited to protein–protein interactions and to date, there is
no work describing the use of rHDLs for determining binding kinet-
ics of small ligands to membrane proteins.
The receptor residence time [16] has developed into an
important consideration in drug discovery. Particularly with
rapid metabolic clearance, the residence time on the target
receptor may be more important than the afﬁnity in determining a
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of ligand binding, speciﬁcally the dissociation rate, is of growing
interest. In this study,we use SPR to examine the afﬁnities and bind-
ing kinetics of ligands to the adenosine A2A receptor (A2AR), which is
the focus of drug discovery efforts for poorly addressed neurological
disorders such as Parkinson’s disease. The A2A receptor has been
thermostabilised in the presence of an antagonist [6], resulting in
a receptor, A2A-StaR2, which maintains binding afﬁnity for antago-
nists while having reduced binding for agonists. The A2A-StaR2
was reconstituted in rHDLs and immobilised on an SPR sensor chip
to determine the afﬁnities and association/dissociation kinetics of
antagonists spanning an almost 36000 fold range in afﬁnity. Our
results show that using stabilised receptors, SPR and rHDLsTable 1
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from American Radiolabeled Chemicals (50 Ci/mmol).
2.2. Protein engineering
The human adenosine A2A-StaR2 used in this work was sta-
bilised in the presence of an inverse agonist (ZM241385) [6]. It
has 8 thermostabilising mutations compared to the wild-type
receptor: A54L, T88A, K122A, N154A, V239A, R107A, L235A and
S277A. The ﬁrst three amino acids are deleted and the protein
has a C-terminal truncation after K315. A deca-histidine tag has
been added at the C-terminus.
The zebraﬁsh apolipoprotein A-I (Zap1) [19] has a PreScission
protease site followed by a hexa-histidine tag at the C-terminus.2.3. Expression and puriﬁcation
The adenosine A2A-StaR2 was expressed using the baculovirus
system. Tni PRO cells were grown in ESF921 medium (Expression
Systems) supplemented with 5% (v/v) foetal bovine serum
(Sigma–Aldrich) and 1% (v/v) penicillin and streptomycin. Cells
were infected at a density of 2.6 million cells per ml with recombi-
nant virus at an approximate multiplicity of infection (MOI) of 1.
Cells were harvested by centrifugation 48 h post-infection.
Membranes were prepared from a one litre cell pellet resus-
pended in 40 mM Tris–HCl pH 7.6, 1 mM EDTA, Complete EDTA
free protease inhibitor cocktail tablets (Roche). Cells were dis-
rupted by a single passage through a microﬂuidizer (processor
M-110L Pneumatic, Microfuidics) cooled with ice (lysis pressure
Table 2
The equilibrium dissociation constant, and association and dissociation rate constants for the A2A-StaR2 when detergent solubilised, in rHDLs and in membranes. ka is expressed
in 1/Ms, kd in 1/s and residence time (1/kd) in min. All pKi values from the literature are for the wild type A2A receptor, except for PhT (A2A-StaR2).
Biacore A2A-StaR2 in DDM micelles Biacore A2A-StaR2 in rHDLs Radioligand binding assay membranes Literature
Theophylline Kinetic pKD 5.71 5.78
Competition pKi 6.28 5.74[22]
SLV320 ka 1.3  105 9.9  105 1.82 ± 0.8  104
kd 7.6  102 3.8  101 3.58 ± 1.6  102
Kinetic pKD 6.23 6.42 5.70
Competition pKi 6.38 6.40[23]
Residence time 0.22 0.04 0.47
DPCPX ka 4.8 ± 0.6  105 4.5 ± 0.9  105 5.10 ± 1.5  104
kd 3.5 ± 0.6  102 4.4 ± 0.5  102 7.66 ± 1.0  103
Kinetic pKD 7.12 6.95 6.81
Competition pKi 7.64 6.89[24]
6.63[25]
Residence time 0.48 0.37 2.18
KW3902 ka 4.5 ± 0.4  105 2.2 ± 0.9  105 4.88 ± 0.4  105
kd 1.5 ± 0.2  102 2.4 ± 0.8  102 1.69 ± 0.4  102
Kinetic pKD 7.46 6.89 7.47
Competition pKi 7.99 6.97[26]
Residence time 1.10 0.69 0.99
XAC ka 1.2 ± 0.2  106 9.2 ± 2  105 2.60 ± 0.1  105
kd 2.6 ± 0.5  102 1.7 ± 0.3  102 2.63 ± 0.2  103
Kinetic pKD 7.68 7.74 7.95
Competition pKi 8.47 9.00[24]
8.05[25]
Residence time 0.65 1.01 6.34
SCH58261 ka 3.5 ± 0.5  106 3.6 ± 2.8  106 2.13 ± 0.4  106
kd 2.3 ± 0.2  102 8.9 ± 4.2  103 7.62 ± 1.2  103
Kinetic pKD 8.19 8.40 8.45
Competition pKi 8.55 9.22[24]
8.96[25]
Residence time 0.74 1.87 2.19
ZM241385 ka 2.0 ± 0.2  106 3.0 ± 0.7  106 6.58 ± 2.7  106
kd 7.9 ± 0.6  104 7.5 ± 1.2  104 3.89 ± 0.1  103
Kinetic pKD 9.40 9.49 9.18
Competition pKi 9.19 9.40[27]
9.10[24]
Residence time 21.14 22.09 4.28
SCH442416 ka 7.9 ± 1.4  105 7.3 ± 1.3  105 3.70 ± 1.2  106
kd 3.3 ± 0.2  103 1.3 ± 0.1  103 6.92 ± 0.5  103
Kinetic pKD 8.33 8.69 8.74
Competition pKi 8.92 10.3[28]
Residence time 4.98 12.63 2.41
PhT ka 8.7 ± 0.7  105 1.2 ± 0.7  107 2.74 ± 0.6  106
kd 1.5 ± 0.1  104 5.8 ± 4  104 2.06 ± 0.1  103
Kinetic pKD 9.74 10.38 9.11
Competition pKi 9.74 8.85[18]
Residence time 108.70 28.97 8.11
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at 204700g and stored at 80 C. Membranes were solubilised
with 2% n-decyl-b-D-maltopyranoside (DM) for 1 h at 4 C followed
by ultracentrifugation to remove insoluble material.
The solubilised material was applied to a 5 ml Ni–NTA (nickel–
nitrilotriacetic acid) superﬂow cartridge (Qiagen) and the protein
eluted with 40 mM Tris–HCl pH 7.4, 400 mM NaCl, 0.15% DM,
280 mM imidazole and 3 mM theophylline. Elution fractions con-
taining the 36 kDa protein were pooled and concentrated. The pro-
tein sample was applied to a Superdex 200 10/300 GL size
exclusion column (GE Healthcare). The ﬁnal protein concentration
was determined using a detergent compatible Bradford assay
(Bio-Rad) and quantitative amino-acid analysis.
Throughout puriﬁcation the concentration of functional, puri-
ﬁed receptor was determined by scintillation proximity assay
(SPA) with a 20 nM concentration of [3H]ZM241385 (40 over
KD) saturating completely the receptor.Zebraﬁsh apolipoprotein A-I (Zap1) was expressed in
Escherichia coli by using a pET28a vector and puriﬁed as previously
described [19].
2.4. Reconstitution into rHDLs
The puriﬁed A2A-StaR2 (ca. 0.5 mg) was reconstituted into rHDLs
as previously described [19] using Zap1 as a scaffold protein
and the following lipids: 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol (POPG) and cholesterol (CHO) in a 3:2:0.5 molar
ratio (Avanti Polar Lipids). The Zap1:lipid ratio was kept around
1:100 and the ratio of A2AR:Zap1 was 1:2.5.
Receptor, phospholipids and scaffold protein were incubated at
4 C for 1 h with rolling agitation before Bio-Beads SM-2 (Bio-Rad)
were added (1 g of beads per ml) to remove the detergent and
initiate disc self-assembly. After overnight incubation at 4 C with
Fig. 1. (A and B) Plots of kd and pKD values, respectively, of A2A-StaR2 in detergent micelles and A2A-StaR2 in rHDLs. (C and D) Plots of kd and pKD/pKi, respectively, of A2A-
StaR2 in cell membranes and A2A-StaR2 in rHDLs.
E. Segala et al. / FEBS Letters 589 (2015) 1399–1405 1403agitation, the hexa-histidine tag of Zap1 was cleaved by adding
0.5 mM DTT and 1 ll of PreScission Protease (GE Healthcare) and
incubating for 1 h at room temperature, leaving the histidine tag
on the receptor to bind the NTA sensor chip.
A2AR-StaR2 rHDLs were separated from aggregated material
and empty discs by gel ﬁltration onto a Superdex 200 10/300 GL
column (GE Healthcare) with 10 mM HEPES pH 7.5, 100 mM
NaCl. Fractions containing the assembled rHDLs were pooled and
concentrated. Final concentration was measured by a BCA assay
and the speciﬁc activity (pmol/mg) of the reconstituted receptor
was measured by SPA.
2.5. Radioligand binding
SPA binding reactions were performed in 200 ll ﬁnal volume
in buffer containing 20 mM HEPES pH 7.4, 1 mM MgCl2, 0.1%
BSA, and 0.15% DM when assays were performed on solubilised
receptors. [3H]ZM241385 (20 nM) was added to copper-chelate
YSi scintillation SPA beads (150 lg/well, PerkinElmer). 10 ng,
50 ng or 100 ng of solubilised A2A-StaR2 or reconstituted
A2A-StaR2 was added per well. Non-speciﬁc binding was deter-
mined in the presence of 10 lM unlabelled ZM241385. The plate
was shaken on a vibrating platform for 1 h at room temperature
before counting on a MicroBeta liquid scintillation counter (SPA
cpm mode, Wallac).
For ﬁltration assays, cell membranes from Sf9 cells expressing
the A2A-StaR2 were incubated in buffer containing 50 mMTris–HCl pH 7.4 with [3H]ZM241385 in a total assay volume of
1 ml with a ﬁnal DMSO concentration of 1%. Assays were per-
formed as previously described [6]. KD values were obtained using
a global ﬁtted one-site binding hyperbola in Prism 5.04 (GraphPad,
San Diego, CA, USA).
Competition binding was performed by incubating membranes
(10 lg/well) with [3H]ZM241385 (1.5 nM) and a range of test
antagonist concentrations (from 104 to 1012 M). Association
and dissociation data were ﬁtted globally in Prism 5.04 to deter-
mine IC50 values. These were converted to Ki values using the
Cheng–Prusoff equation K i ¼ IC50=ð1þ ½L=KDÞ.
Association kinetic parameters for [3H]ZM241385 were deter-
mined by adding the same cell membranes (10 lg protein/well)
and 0.1, 0.3 or 0.9 nM radioligand at time points of 0, 20, 40, 48,
52, 56, 58, 59, 59.5 and60 min.Dissociation kinetic parameterswere
determinedbypre-equilibratingmembranes and [3H]ZM241385 for
1 h; a saturating concentration of unlabelled CGS15943 (1 lM) was
then added at the same time points as above. Kinetics of binding of
unlabelled compounds were determined using the method of
Motulsky and Mahan [20]. Association curves for [3H]ZM241385
were determined in the absence or presence of three concentrations
of competitive antagonist (typically 0.3, 1 and 3  KD value).
Association and dissociation rate constants for unlabelled com-
pounds were calculated by global analysis of the association data
sets, as previously described [21]. Ligand-receptor residence times
were calculated as 1/kd.
All assays were conducted twice in triplicate.
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SPR analyses were carried out at 10 C on a Biacore T200 instru-
ment using NTA sensor chips (GE Healthcare) with a ﬂow rate of
30 ll/min. The running buffer was PBS with 0.05 mM EDTA and
5% DMSO. 0.1% n-dodecyl-b-D-maltoside (DDM) was added for
experiments with the solubilised receptor.
Ligands were prepared over a double-dilution series (5 concen-
trations) and injected in either a multi- or a single-cycle format
depending on their kinetic parameters. The actual concentrations
aswell as contact and dissociation times varied between the ligands
depending on the kinetics and afﬁnity of interaction. The data were
ﬁtted to a 1:1 interaction model using the kinetics evaluation
software from Biacore. A minimum of three measurements were
recorded for each interaction. All calculations of correlation coefﬁ-
cients are on a logarithmic basis, i.e. using pka, pkd, pKD and pKi.
3. Results
3.1. Puriﬁcation of A2A-StaR2 and reconstitution into rHDLs
The C-terminally His10-tagged A2A-StaR2 receptor was puriﬁed
to near homogeneity through a single step of metal chelate afﬁnity
chromatography. During puriﬁcation, theophylline, a low afﬁnity
ligand (KD 2 lM) provided additional stability to the receptor.
0.5 mg of receptor was reconstituted into rHDLs using Zap1 in a
1:2.5 A2AR to scaffold protein ratio. The ﬁnal yield of A2AR and
Zap1 was 220 lg. As the A2AR is approximately half of the disc com-
plex, approximately 20% of the initial puriﬁed receptor has been
reconstituted into rHDLs. Copper-chelate SPA assays showed that
both solubilised and reconstituted receptors bound
[3H]ZM241385 with high Bmax values, 97% and 92% of active
receptor fractions, respectively.
3.2. SPR experiments on A2A-StaR2
To compare the pharmacology of A2A-StaR2 in rHDLs with that
of the receptor in detergent micelles, 9 antagonists were tested by
SPR. These ligands have molecular weights ranging from 180 Da
(theophylline) to 464 Da (XAC) and reported afﬁnities for the
wild-type A2A receptor from 50 pM (SCH442416) to 1.8 lM
(theophylline) [18,22–28].
The A2A-StaR2 in DDM micelles and in rHDL bilayers were suc-
cessfully immobilised on the Biacore sensor chip, with a slightly
lower increase observed for the A2A-StaR2-rHDLs (increase by
5000–7000 resonance units, RU) compared to the solubilised
receptor (increase by 10000–12000 RU). Both samples gave mea-
surable amplitudes for all compounds tested.
Concentration response experiments for A2A-StaR2 in DDM
micelles and rHDL bilayers are shown for the compounds tested
in Table 1. The sensorgrams are quite different between com-
pounds, requiring a move from multi-cycle to single-cycle experi-
ments for those of higher afﬁnity. The concentration response
experiments provided afﬁnities and association and dissociation
rate constants for all of the ligands tested except theophylline
(Table 2). For this ligand, SPR data approach saturation for both
forms of the receptor and afﬁnities can be calculated; however,
the association and dissociation rates were too fast to allow mea-
surement of rate constants with conﬁdence. The correlation
between the association rate constants measured for A2A-StaR2
in DDM micelles and in rHDL bilayers is poor (R2 = 0.23, data not
shown), whereas the correlations between these two forms of
the receptor for the dissociation rate constants (R2 = 0.82) and
the afﬁnities (R2 = 0.96) are very good (Fig. 1A and B).3.3. Radioligand binding experiments on A2A-StaR2 in cell membranes
In addition to the SPR experiments on the A2A-StaR2 in DDM
micelles and in rHDLs, radioligand binding studies were performed
on the receptor expressed in Sf9 insect cells. The saturation and
kinetically-derived pKD values for [3H]ZM241385 (9.19 and 9.18,
respectively) for A2A-StaR2 in cell membranes are in good agree-
ment with the pKD values measured by SPR for the solubilised
receptor (9.40) and the receptor in rHDLs (9.49). The association
and dissociation rate constants of [3H]ZM241385 are also close to
the values obtained by SPR for the unlabelled ZM241385 (Table 2).
Unlabelled adenosine receptor antagonists were tested in com-
petition binding experiments against [3H]ZM241385, and pKi val-
ues are reported in Table 1. XAC, SCH58261, ZM241385,
SCH442416 and PhT show high afﬁnity binding to A2A-StaR2 in
membranes, with pKi values close to the published ones for the
wild-type receptor, whereas theophylline, SLV320, DPCPX and
KW3902 have afﬁnities between 10 nM and 2 lM, also in agree-
ment with literature data.
Variations in the association and dissociation rate constants are
observed when comparing data from SPR experiments with those
from radioligand binding experiments (Table 2). The correlation
between association rate constants for A2A-StaR2 in detergent
and in membranes is reasonable (R2 = 0.59, data not shown), while
correlation between A2A-StaR2 in rHDLs and in membranes is poor
(R2 = 0.26, data not shown). The correlations between the dissocia-
tion rate constants are reasonable, for receptors in membranes and
DDM micelles (R2 = 0.46) and for receptors in membranes and
rHDLs (R2 = 0.59) (Fig. 1C). The pKD values generated by SPR corre-
late well with pKi values from radioligand binding experiments in
membranes (R2 = 0.89 between receptors in membranes and deter-
gent; R2 = 0.83 between receptors in membranes and rHDLs)
(Fig. 1D).
The pKD values generated by SPR are also comparable with the
published pKi values from competitive radioligand binding experi-
ments of the wild-type A2A receptor in cell membranes or native
tissue (Table 2).
4. Discussion
There is mounting evidence to suggest that binding kinetics can
inﬂuence the efﬁcacy of a drug [16,17], hence there is often a desire
to rank compounds by their dissociation kinetics prior to selecting
a development candidate. Although previous data [7,29] from a
stabilised adenosine A2A receptor solubilised and immobilised on
a biosensor chip support its use for proﬁling compound binding
afﬁnities and kinetics, there are circumstances where this format
may not be ideal. Ligands with poor solubility and high clogP can
partition within micelles [30], reducing the effective concentration
and distorting estimation of afﬁnities and kinetics. Additionally,
detergents do not provide the same lateral pressure and charge
distribution as a lipidic leaﬂet and could disrupt high afﬁnity bind-
ing [19,31]. Third, detergents interfere with binding of additional
components such as G proteins [15,32].
To explore a format which could address these concerns,
A2A-StaR2 was reconstituted into rHDLs and tested by SPR with
the same set of antagonists as the solubilised receptor. The higher
molecular weight of the GPCR-rHDL complex (approximately 160
to 180 kDa) vs A2A-StaR2 micelles (approximately 100 kDa)
reduces the number of receptors immobilised on the chip, increas-
ing the need for a high proportion of receptors able to bind ligands
to obtain usable sensorgrams (Table 1). This favours the use of sta-
bilised receptors which allow high fractions of active receptor to be
maintained during puriﬁcation and reconstitution.
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and cholesterol maintained the afﬁnities and dissociation rates
for the A2A-StaR2 antagonists (Table 1 and Fig. 1). As for the solu-
bilised receptor, SPR afﬁnities and dissociation rates are in line
with those published in the literature and obtained by competitive
radioligand binding kinetics.
In this study correlations between compounds measured in dif-
ferent formats are generally very good for afﬁnities, reasonable for
dissociation rate constants, and poor for association rate constants.
The very good correlation for afﬁnities gives us conﬁdence that SPR
can be used with stabilised GPCRs reconstituted into rHDLs as well
as solubilised in detergent for proﬁling ligands. There is no loss in
binding afﬁnity for the stabilised receptor whereas wild-type
GPCRs often show rightward shifts to lower afﬁnities after deter-
gent solubilisation [11,19,31]. The fact that the worst correlations
are for association rate constants is not surprising, as their calcula-
tion directly depends on knowledge of the ligand concentration,
which may be subject to unaccounted errors, such as from insolu-
bility or partitioning. The reasonable correlation of dissociation
rate constants would be sufﬁcient to support lead optimisation
where the major use is expected to be ranking of compounds based
on relative rates. As the residence times are derived from the dis-
sociation rate constants, equivalent trends are observed. In each
case DPCPX has the shortest residence time and PhT the longest,
but the range varies considerably (from 0.22 to 108 min for the
A2A-StaR2 in DDM micelles, to 0.04 to 29 min for the rHDL discs,
to 0.47 to 8.1 min for the membranes). Hence while these can be
used to compare compounds, it remains to be established which
format is closest to an in vivo situation.
In conclusion, using a thermostabilised adenosine A2A receptor,
we have shown that the immobilisation of a receptor reconstituted
into rHDLs on a sensor chip can provide useful afﬁnities and binding
kinetics data. As the SPR technique does not require competition
with a labelled compound it is well suited to monitor binding at a
range of sites, such as those of allosteric modulators. This is the ﬁrst
time the measurement of ligand afﬁnities and binding kinetics has
been achieved by SPR on a rHDL-reconstituted GPCR in the absence
of radio- or ﬂuorescently labelled tracer molecules. This is a new
approach to characterise the interactions between small molecules
and GPCRs and it provides another means for using binding kinetics
during compound optimisation. The data presented here do not
clearly indicate whether the detergent micelles or rHDLs are the
superior format. Rather, both are reliable, and it is more likely that
the choice of format may depend on the system to be studied, with
detergent micelles easier to produce and giving higher sensitivity,
and rHDLs offering a more native-like environment and avoiding
problems of ligands partitioning into micelles. In addition the
rHDL format allows the binding of ligands to GPCRs to be studied
in the presence of other components, such as G proteins.
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